Physician profile
Mitchell Kamrava
NPI 1982806097
$29,818.81
in general payments reported to CMS, 2019-2025
13 companies · $18K in 2025
The $18K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $137 · 2021: $380 · 2022: $2,272 · 2023: $4,430 · 2024: $4,271 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $2,089 · Travel and Lodging: $1,025 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,430.00 |
| Food and Beverage | $2,089.34 |
| Travel and Lodging | $1,025.40 |
| Education | $124.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gt Medical Technologies, INC | $16,041.17 | 2019-2025 | Gammatile |
| Seagen INC. | $4,132.08 | 2022-2023 | Tivdak |
| Merck Sharp & Dohme LLC | $3,965.00 | 2024 | |
| Theragenics Corporation | $3,420.17 | 2021-2025 | |
| Ethicon INC. | $865.00 | 2025 | |
| Blue Earth Diagnostics | $294.79 | 2024-2025 | Posluma |
| Boston Scientific Corporation | $269.98 | 2019-2024 | Spaceoar System |
| Bioprotect Medical, INC. | $210.07 | 2025 | Bioprotect Balloon Implant System |
| Glaxosmithkline, LLC. | $163.99 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $133.65 | 2023 | Orgovyx |
| Elekta, INC. | $130.00 | 2019 | |
| Angiodynamics, INC. | $105.69 | 2019 | |
| Pfizer INC. | $87.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kamrava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.